Cipher Pharmaceuticals Inc. - Third Quarter 2026 Financial Results Call - DEFI TECHNOLOGIES INC

Financial Performance:

• Net revenue was $12.7 million for Q3 2026, a 1% year-over-year decrease; YTD revenue was $37.3 million, down 3%.
• Net income was $10.9 million ($0.42/diluted share) for Q3 and $21.1 million ($0.81/diluted share) for YTD, significantly impacted by a $5.7 million arbitration award received post-quarter.
• Adjusted EBITDA was $7.2 million for Q3 (57% margin) and $21.8 million for YTD (58% margin), excluding non-recurring arbitration recoveries.
• Gross margin remained robust at 82% for Q3 and 81% YTD; product revenue decreased 5% to $11.5 million in Q3 due to Natroba volume drops.
• Licensing revenue surged 62% to $1.2 million in Q3, driven by Absorica and LipoFin shipments; total product revenue from Natroba fell 12% to $7.1 million.
• The company is debt-free with $15.3 million in cash at quarter-end, rising to approx. $20 million after the $5.7 million arbitration payment in October, plus $65 million undrawn credit facility availability.

Guidance and Future Outlook:

• Management anticipates Health Canada's Netroba drug submission review to conclude in Q1 2027, targeting markets with high unmet need for lice/scabies treatments.
• Expectations for Natroba revenue improvement continue in the U.S. via commercial payer and retail channel expansion to offset Medicaid volume reductions.
• Canadian Epirus growth is projected to accelerate following public drug plan listings in B.C., Quebec, and Alberta, expanding the addressable market.
• Strong cash position and positive operating cash flows are positioned to fund growth strategies, including M&A, in-licensing, and out-licensing initiatives.
• No specific revenue guidance numbers were provided for the upcoming quarter, though management expressed optimism for short-term deal execution in business development.

Business Segments and Product Lines:

• Natroba: Q3 revenue down 12% YoY due to Medicaid cuts, but showed sequential improvement with a 14% increase over Q2; expanding U.S. non-Medicaid channels and seeking out-licensing globally.
• Epirus: Canadian revenue up 8% to $4.3 million; market share in isotretinoin reached 48.7% (up 1.6 points); secured public reimbursement in three key provinces to drive adoption for severe nodular acne.
• Acquisition Strategy: Active pursuit of in-licensing complementary products and company acquisitions; appointment of Rajiv DeSilva to the Board to leverage M&A expertise.
• Out-licensing: Engaged a consulting firm to facilitate out-licensing of Natroba and Epirus outside North America; receiving increased interest from global partners.

Market and Competitive Landscape:

• Natroba addresses the unmet need of permethrin resistance in both head lice and scabies markets globally; positioned as a superior single-treatment option.
• Epirus is the leading isotretinoin product in Canada, benefiting from a lack of effective public coverage for the majority of the patient population until recent provincial listings.
• Competitive pressure exists from OTC head lice products where patients often self-treat without understanding efficacy issues with standard permethrin 1%.
• Management is actively engaging with payers to secure Medicaid coverage renewals in states beyond Illinois, though timelines vary by state.

Risks and Challenges:

• Medicaid Volatility: Continued reductions in Medicaid covered lives negatively impacting Natroba volumes in the U.S.
• Arbitration Uncertainty Resolved but One-off: While the $5.7M award was finalized, it is non-recurring; future results rely on core commercial performance.
• Regulatory Timelines: Delays or rejections in international regulatory reviews (e.g., Health Canada) could impact global expansion plans for Natroba.
• Deal Execution Risk: M&A and licensing targets may not materialize due to lengthy negotiation periods or valuation mismatches.
• Market Penetration: Educating consumers on the superiority of Natroba over common OTC alternatives remains a marketing challenge.

Management Commentary and Tone:

• Tone was confident and cautious; highlighted the company's "highly profitable" status and strong balance sheet while managing expectations on deal timing.
• Emphasized the strategic value of the arbitration win and the 15% royalty on Absorica sales through 2040 as a long-term revenue stream.
• Management stressed the importance of board strengthening (DeSilva appointment) to navigate complex M&A and corporate strategy.
• Expressed optimism about finding the "right fit" for acquisitions but declined to provide specific timelines to avoid leveraging competitors.

Analyst Questions and Answers:

• Medicaid Step-Thru: Confirmed ongoing pursuit of Medicaid step-through processes in states other than Illinois; decisions are clinical-level and state-specific with no fixed timeline.
• Walmart Stocking: Refused to quantify specific unit volumes attributed to the Walmart fill-in program to protect contract sensitivities, noted program covers all US stores.
• Capital Allocation: Discussed balancing share buybacks with M&A; noted current NCIB is restrictive, considering a Substantial Issuer Bid (SIB) for more flexibility; no immediate buyback increase expected if a major deal closes.
• Natroba Market Share: Confirmed ability to capture share from permethrin resistance is a material revenue driver, particularly in the scabies segment where Natroba is the only superior alternative.
• Absorica Marketing: Confirming discussions with Sun Pharmaceuticals for contract extension and evaluating proposals from other generic outfit partners.
• Pipeline Synergy: No immediate relevant pipeline assets from partner Galderma, though constant communication continues.

Other Key Points:

• The arbitration award recognized in financials includes $4.2M CAD compensatory damages, 15% royalty on Absorica sales in Canada (2026–2040), and fee recoveries.
• SG&A expenses dropped 68% YoY in Q3 to $1.2M, driven by legal cost recoveries from the arbitration, one-time costs in the prior year, and operational efficiencies.
• The company has 33% of its Q3 revenue generated from licensing deals, up significantly from prior periods.
• The Q3 2026 financial results reflect a unique convergence of operational stability and a major legal victory, with the latter inflating net income but excluded from adjusted EBITDA.